Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase NA 2Phase 1/2 1Phase 1 1

Status

Recruiting 4Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Sarcoma 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1GIST 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 90Gemcitabine 81Paclitaxel 80Docetaxel 73Capecitabine 64Oxaliplatin 53Specimen Handling 51Fluorouracil 51Magnetic Resonance Spectroscopy 49Radiotherapy 48Bevacizumab 48Dexamethasone 45Cyclophosphamide 44Leucovorin 38Drug Therapy 38Irinotecan 36Doxorubicin 36Pemetrexed 35Injections 30Trastuzumab 28Vincristine 27Rituximab 27Radiosurgery 25Prednisone 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24Lenalidomide 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × olverembatinib × Clear all
NCT06051409 2026-04-30

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Ascentage Pharma Group Inc.

Phase 3 Recruiting
350 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07152041 2025-09-03

CAMS-Ph+ B-ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 3 Recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06423911 2025-06-03

POLARIS-2

Ascentage Pharma Group Inc.

Phase 3 Recruiting
285 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting
40 enrolled
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡